Why the study?
Is prophylactic implantation of a cardioverter defibrillator cost-effective compared to conventional treatment in patients with reduced left ventricular systolic function?
Is prophylactic implantation of a cardioverter defibrillator cost-effective compared to conventional treatment in patients with reduced left ventricular systolic function?
Prophylactic ICD implantation in patients with reduced LVEF is likely cost-effective in a European healthcare setting, with an estimated cost of €31,717 per QALY gained.
No takes yet. Share an insight, caveat, or question.
May support prophylactic ICDs in reduced LVEF from a European payer perspective; extends trial-derived efficacy with lifetime Markov modeling.
Cowie et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: